CONVERT

NCT00433563 📎

Regimen

Experimental
66 Gy in 33 once-daily fractions of 2 Gy over 45 days + cisplatin-etoposide
Control
45 Gy in 30 twice-daily fractions of 1.5 Gy over 19 days + cisplatin-etoposide

Population

Adults with cytologically or histologically confirmed limited-stage SCLC, ECOG 0-2

Key finding

mOS 30 mo (twice-daily) vs 25 mo (once-daily); HR 1.18 (95% CI 0.95-1.45, p=0.14); 2-yr OS 56% vs 51%; twice-daily remains standard of care

Source: PMID 28642008

Timeline

    Guideline citations

    • NCCN SCLC (p.25)
    • CSCO SCLC 2025 (p.40)⚠️ OCR source